Nexstim develops the Navigated Brain Stimulation (NBS) system, a non-invasive, image-guided transcranial magnetic stimulation platform used for functional brain mapping and therapeutic neuromodulation. The NBS System is positioned as a standard for pre-operative functional brain mapping prior to tumor resection or epilepsy surgery, with accuracy shown to be equivalent to direct cortical stimulation. The technology also underpins potential neuromodulation therapies for stroke, depression, pain and other neurological conditions. The NBS System is approved for use in both the U.S. and European markets for direct, non-invasive cortical mapping, with FDA clearance for assessment of the primary motor cortex for pre-procedural planning. Nexstim highlights ongoing clinical evidence supporting its value in neurosurgery and aims to pioneer navigated stimulation therapy in stroke and other neurotherapy markets. Financially, the company announced additional equity financing as part of a latest round totaling €13.4 million and has raised over €30 million to date.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

May 2011